Table 1: Baseline characteristics of the study population.

PlaceboRJ

Subject number2121N. D
Postmenopausal period
 1–3 years1615
 3–5 years56
Age (years)54.4 ± 3.054.4 ± 2.61.000
BMI (kg/m2)21.2 ± 2.621.0 ± 3.00.790
Each menopausal VAS score
 Hot flashes41.5 ± 35.044.2 ± 32.90.797
 Sweating44.6 ± 30.252.0 ± 30.10.436
 Insomnia27.3 ± 27.430.7 ± 26.10.684
 Light sleep42.0 ± 28.543.2 ± 23.00.873
 Irritability32.5 ± 33.034.0 ± 25.00.871
 Anxiety28.7 ± 26.630.5 ± 22.50.818
 Anxious trifles35.1 ± 31.135.5 ± 25.80.970
 Depressive mood30.2 ± 24.333.4 ± 26.30.685
 Fatigue39.0 ± 23.742.5 ± 22.00.620
 Eye strain60.7 ± 31.758.6 ± 27.80.821
 Forgetfulness58.3 ± 28.257.7 ± 26.40.942
 Dizziness27.1 ± 29.027.4 ± 28.70.970
 Palpitation25.9 ± 27.918.4 ± 22.20.342
 Chest tightness17.2 ± 20.77.1 ± 10.10.051
 Headache46.9 ± 33.834.9 ± 29.40.229
 Neck stiffness65.4 ± 31.763.6 ± 31.60.854
 Backache and low back pain47.0 ± 34.747.2 ± 30.90.989
 Joint pain39.0 ± 33.337.5 ± 26.60.875
 Cold hands and feet38.4 ± 28.041.7 ± 30.40.717
 Numbness in the legs or arms25.1 ± 28.921.8 ± 26.50.703
 Sensitive to sounds31.5 ± 32.218.9 ± 20.50.137

RJ, enzyme-treated Royal Jelly. The values are means ± SD.